Stockscreener 앱 받기
13.10
1.71%
0.22
시장 영업 전:
12.57
-0.53
-4.05%
전일 마감가:
$12.88
열려 있는:
$12.88
하루 거래량:
755.31K
Relative Volume:
1.30
시가총액:
$663.16M
수익:
$89.04M
순이익/손실:
$-241.08M
주가수익비율:
-2.4905
EPS:
-5.26
순현금흐름:
$-194.72M
1주 성능:
-1.21%
1개월 성능:
+13.67%
6개월 성능:
+29.96%
1년 성능:
+43.01%
1일 변동 폭
$12.82
$13.77
1주일 범위
$12.05
$13.77
52주 변동 폭
$5.035
$13.93
Regenxbio Inc Stock (RGNX) Company Profile
명칭
Regenxbio Inc
전화
240-552-8181
주소
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
RGNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
13.10 | 652.03M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-11 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-02-07 | 재개 | Raymond James | Outperform |
| 2024-11-15 | 재개 | Morgan Stanley | Overweight |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-06-07 | 개시 | Goldman | Buy |
| 2024-03-11 | 개시 | H.C. Wainwright | Buy |
| 2024-03-08 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | 재개 | Raymond James | Outperform |
| 2023-11-01 | 개시 | Stifel | Buy |
| 2023-06-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-15 | 개시 | Wedbush | Neutral |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-01-06 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | 재확인 | Chardan Capital Markets | Buy |
| 2019-06-14 | 재개 | Raymond James | Outperform |
| 2019-06-05 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-25 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-02-05 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | 재확인 | Chardan Capital Markets | Buy |
| 2018-11-08 | 재확인 | BofA/Merrill | Neutral |
| 2018-08-08 | 재확인 | Chardan Capital Markets | Buy |
| 2018-07-23 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | 재확인 | Chardan Capital Markets | Buy |
| 2018-05-09 | 재확인 | Barclays | Overweight |
| 2018-04-09 | 재확인 | Chardan Capital Markets | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-02-13 | 개시 | Mizuho | Neutral |
| 2017-11-09 | 재개 | Morgan Stanley | Overweight |
모두보기
Regenxbio Inc 주식(RGNX)의 최신 뉴스
Why global investors buy REGENXBIO Inc. (RB0) stock2025 Market WrapUp & Safe Capital Allocation Plans - Newser
Will REGENXBIO Inc. (RB0) stock profit from fiscal stimulus2025 Big Picture & Safe Entry Zone Identification - Newser
Can REGENXBIO Inc. stock resist market sell offsQuarterly Profit Review & Technical Pattern Based Signals - Newser
Is REGENXBIO Inc. stock resilient to inflationGold Moves & Fast Exit Strategy with Risk Control - Newser
What insider trading reveals about REGENXBIO Inc. stockExit Point & Smart Investment Allocation Insights - Newser
Will REGENXBIO Inc. (RB0) stock see valuation expansionWeekly Trade Analysis & Reliable Trade Execution Plans - Newser
Will REGENXBIO Inc. (RB0) stock announce special dividend2025 Top Gainers & AI Enhanced Trading Alerts - Newser
REGENXBIO announces royalty monetization agreement for up to $250M - MSN
Commercial Lessons From The Cell And Gene Therapy Frontlines - Citeline News & Insights
How (RGNX) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
26,773 Shares in REGENXBIO Inc. $RGNX Bought by Rockefeller Capital Management L.P. - MarketBeat
Gainers Report: Is REGENXBIO Inc. stock a contrarian buyJuly 2025 Summary & Risk Managed Trade Strategies - BỘ NỘI VỤ
REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript - The Globe and Mail
Regenxbio files $300M mixed securities shelf - MSN
Transcript : REGENXBIO Inc. Presents at Stifel 2025 Healthcare Conference, Nov-11-2025 01 - marketscreener.com
Regenxbio files $300M mixed shelf offering - MSN
Regenxbio (RGNX) Files for $300M Securities Offering - GuruFocus
Regenxbio files for mixed shelf of up to $300 millionSEC filing - marketscreener.com
[S-3] REGENXBIO Inc. Shelf Registration Statement | RGNX SEC FilingForm S-3 - Stock Titan
REGENXBIO to Participate in Upcoming Investor Conference - PR Newswire
Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet? - 富途牛牛
REGENXBIO (Nasdaq: RGNX) Fireside Chat at Piper Sandler 37th Healthcare Conference - Stock Titan
Regenxbio up 4% following additional data on Duchenne gene therapy asset - MSN
RGNX S-8及美國證券交易委員會申報文件 - Yahoo 財經
Chardan Capital Maintains Buy Rating for RGNX with $52 Price Tar - GuruFocus
Is REGENXBIO Inc. (RB0) stock safe for risk averse investors2025 Earnings Impact & Precise Swing Trade Alerts - newser.com
Chardan Capital Maintains REGENXBIO (RGNX) Buy Recommendation - MSN
Will REGENXBIO Inc. (RB0) stock profit from AI boomJuly 2025 PostEarnings & Real-Time Buy Zone Alerts - newser.com
How REGENXBIO Inc. stock responds to policy changes2025 Investor Takeaways & Long-Term Growth Portfolio Plans - newser.com
Visualizing REGENXBIO Inc. stock with heatmapsWeekly Trade Recap & Intraday High Probability Alerts - newser.com
Reversal indicators forming on REGENXBIO Inc. stock2025 Breakouts & Breakdowns & Intraday High Probability Alerts - newser.com
Trading Systems Reacting to (RGNX) Volatility - news.stocktradersdaily.com
Will REGENXBIO Inc. stock split again soonTrade Ideas & Precise Buy Zone Tips - newser.com
What data driven models say about REGENXBIO Inc.’s futurePortfolio Value Summary & Consistent Income Trade Recommendations - newser.com
Regenxbio Inc (RGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.10%
1.10%
자본화:
|
볼륨(24시간):